Introduction {#sec1}
============

Approximately 100 million people worldwide are infected with the intestinal nematode *Strongyloides stercoralis* (StrS). This roundworm is endemic in tropical and subtropical regions.[@bib1], [@bib2], [@bib3], [@bib4] StrS has an autoinfective cycle that allows it to survive and replicate in a human host for many years.[@bib4] StrS has 2 important life stages, namely, filarial and rhabditiform. In the filarial stage, StrS enters its human host percutaneously through feces-contaminated soil. In the rhabditiform stage, StrS lays eggs that hatch into larvae in the duodenum and are passed into the stool. Most patients with StrS infection remain asymptomatic. Although parasitic infections are known to be associated with immune complex−mediated glomerular lesions, StrS-associated glomerulopathy has not been well documented.

Nephrotic syndrome has rarely been associated with StrS infection.[@bib5], [@bib6], [@bib7], [@bib8] Minimal change disease is the most common glomerular disease reported in association with StrS infection. The pathophysiologic link between StrS infection and nephrotic syndrome is not well defined. As most primary podocytopathies, including minimal change disease and primary focal segmental glomerulosclerosis (FSGS), are thought to be mediated by circulating permeability or immune factors that act on the podocyte,[@bib9] the potential exists for infections to serve as immunologic triggers for these conditions. This scenario is reminiscent of the reported onset of minimal change disease following diverse immune stimuli such as viral infection, allergy, or immunizations. Tip variant is the histologic subtype of primary FSGS that most closely approximates minimal change disease with respect to its abrupt onset of nephrotic syndrome, potential for relapse, low risk of progression to renal failure, and high rate of responsiveness to steroid therapy.[@bib10], [@bib11], [@bib12] Prognosis can be poor in patients with StrS infection and concomitant nephrotic syndrome if they are not treated appropriately,[@bib7], [@bib8] and early diagnosis and treatment of StrS infection improves outcomes. FSGS is a common cause of nephrotic syndrome in adults worldwide,[@bib13], [@bib14] but associations with helmintic infection are rare. We report the first case of tip variant FSGS associated with StrS and review the literature on StrS-associated nephrotic syndrome.

Case Report {#sec2}
===========

A 36-year-old Guatemalan man presented with sudden onset of anasarca and nephrotic syndrome. Laboratory data showed marked proteinuria (spot urine total protein to creatinine ratio, 10.6) and profound hypoalbuminemia (serum albumin, 0.4 g/dl). Serum creatinine was normal (0.5 mg/dl). The patient was admitted for workup and management of edema with i.v. diuretics. Past medical history included biopsy-documented tip variant FSGS at the age of 25 years that had responded to a 6-week course of corticosteroid therapy ([Figure 1](#fig1){ref-type="fig"}a and b). At the time of the first biopsy, there was no known history or symptoms of StrS infection, although specific testing for Strs was not performed. A repeat kidney biopsy performed during this hospitalization showed relapse of tip variant FSGS with severe podocyte foot process effacement ([Figure 1](#fig1){ref-type="fig"}c and d).Figure 1(a,b) Kidney biopsy 1 (performed in 2006). Light microscopy showing tip variant focal segmental glomerulosclerosis (FSGS), with a cellular segmental lesion containing endocapillary foam cells that protrudes into the tubular pole and forms an adhesion to the tubular orifice, consistent with a tip lesion (hematoxylin and eosin, original magnification ×600) (a). Another glomerulus contains a segmental cellular lesion of sclerosis with hypertrophy of the overlying podocytes (hematoxylin and eosin, original magnification ×600 (b). (c,d) Kidney biopsy 2 (performed in 2015). Light microscopy showing a small synechia (adhesion) between the peripheral glomerular tuft and Bowman capsule at the origin of the tubular pole, forming a tip lesion (Jones methenamine silver, original magnification ×400). By electron microscopy, there is diffuse foot process effacement with microvillous transformation of the podocyte cytoplasm. The glomerular basement membrane is unremarkable and no electron-dense deposits are identified (electron micrograph, original magnification ×10,000).

Kidney Biopsy Findings {#sec2.1}
----------------------

### Biopsy 1 (Performed in 2006) {#sec2.1.1}

Of the 15 glomeruli sampled for light microscopy, 2 contained segmental cellular lesions of sclerosis with endocapillary hypercellularity, including mononuclear cells and foam cells, with swelling of the overlying podocytes. One of these lesions had an adhesion to the tubular pole, forming a tip lesion. The remaining glomeruli were histologically unremarkable. There was focal mild acute tubular injury. No significant tubular atrophy or interstitial fibrosis was identified. Vessels were unremarkable. Immunofluorescence staining was negative for all immune reactants (including IgG, IgM, IgA, C3, C1q, fibrinogen, albumin κ and λ light chains) in the 6 glomeruli studied. Electron microscopy (3 glomeruli sampled) revealed diffuse effacement of podocyte foot processes involving 95% of the total glomerular capillary surface area. The glomerular basement membranes were unremarkable. No electron dense deposits were identified.

### Biopsy 2 (Performed in 2015) {#sec2.1.2}

Among the 12 glomeruli sampled for light microscopy, 2 were globally sclerotic. Three glomeruli contained segmental small adhesions between the tuft and the tubular outlet, forming small tip lesions. The remaining 7 glomeruli were histologically unremarkable. The tubulointerstitial compartment was well preserved, with no evidence of tubular atrophy or interstitial fibrosis. There was minimal arteriolar hyalinosis. Immunofluorescence (5 glomeruli studied) revealed 1+ segmental mesangial positivity for IgM only. By electron microscopy (7 glomeruli sampled), extensive foot process effacement involved 90% to 95% of the total glomerular capillary surface area associated with microvillous transformation of the podocyte cytoplasm. No glomerular basement membrane abnormalities or electron-dense deposits were detected.

Clinical Follow-up {#sec2.2}
------------------

A detailed history revealed that the patient had recently traveled to El Salvador and subsequently suffered episodic abdominal pain and diarrhea with peripheral eosinophilia of 3.5 K/μl (41%). His stool ova and parasite smear confirmed the presence of StrS larvae, and the result of a serologic test for StrS antibody was positive. Serologic testing for hepatitis B surface antigen, hepatitis C antibody, antinuclear antibody, antineutrophilic cytoplasmic antibodies, anti−glomerular basement membrane antibody, and HIV antibody were all negative. Serum complement C3 and C4 levels were normal. Serum immunofixation showed no evidence of monoclonal gammopathy. A kidney sonogram revealed normal-sized kidneys. Conservative management with lisinopril, atorvastatin, and diuretics was initiated, with no improvement in edema and with worsening of renal function. Ivermectin 12 mg daily for a total of 7 days was initiated to treat the parasitic infection. No immunosuppressive therapy was given to avoid the risk of exacerbating infection. One month after ivermectin therapy, edema improved, and within 2 months, the nephrotic syndrome resolved. [Figure 2](#fig2){ref-type="fig"} summarizes the changes in laboratory findings over time following initiation of antihelmintic treatment. By 18 months following anti-Strs therapy, the patient was in complete remission of nephrotic syndrome, without resorting to glucocorticoid therapy.Figure 2Time course of nephrotic syndrome response in relation to antihelmintic therapy.

Discussion {#sec3}
==========

Glomerular diseases associated with StrS have rarely been reported. A total of 18 cases of StrS-associated nephrotic syndrome have been reported in the literature[@bib5], [@bib6], [@bib7], [@bib8], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27] and are summarized in [Table 1](#tbl1){ref-type="table"}.Table 1Literature review: *Strongyloides stercoralis*−associated nephrotic syndrome: clinical features, treatment, and renal and patient outcomes in reported casesReferenceAge (yr)SexKidney biopsy findingsCorticosteroid usedTreatmentRenal remissionPatient outcomeWillis et al. 1966[@bib15]26MFSGSYesDithiazinine and thialbendazoleNoSurvivedWillis et al. 1966[@bib15]22MGlomerulonephritis, (type not specified)YesDithiazinine and thialbendazolenoSurvivedCruz et al. 1966[@bib16]22MNBYesThialbendazoleNoDiedCruz et al. 1966[@bib16]10FNBYesThialbendazoleNoDiedCruz et al. 1966[@bib16]34FNBYesThialbendazoleNoDiedCruz et al. 1966[@bib16]5MNBYesThialbendazoleNoDiedWong et al. 1998[@bib17]42FMCDYesThiabendazole, abendazoleYesSurvivedMori et al. 1998[@bib18]62MMCDNoIvermectinYesSurvivedYee et al. 1999[@bib19]55MMCDYesThiabendazoleYesSurvivedMorimoto et al. 2002[@bib20]60FMCDYesNoneNoDiedMitsunga et al. 2003[@bib21]75MNBYesIvermectinYesSurvivedSeet et al. 2005[@bib7]51MNBNoIvermectinYesSurvivedHsieh et al. 2006[@bib22]72MMCDNoIvermectinYesSurvivedSathe et al. 2006[@bib23]38FMPGNYesNoneNoDiedLam et al. 2006[@bib24]55MMCDYesThialbendazoleYesSurvivedChan et al. 2008[@bib25]77FNBNoAlbendazoleYesSurvivedMiyazaki et al. 2010[@bib26]69MMCDYesIvermectinYesDiedLi Cavoli et al. 2011[@bib27]25MMCDYesAlbendazoleYesSurvivedCurrent case36MFSGSNoIvermectinYesSurvived[^1]

Minimal change disease is the most common glomerular disease, reported in 8 patients with StrS infection.[@bib17], [@bib18], [@bib19], [@bib20], [@bib22], [@bib24], [@bib26], [@bib27] Most of these patients received corticosteroid treatment. To the best of our knowledge only 1 case of StrS-associated FSGS has been reported in the literature. The latter patient received both corticosteroid and antihelmintic therapy.[@bib15] In 7 of the 18 cases a kidney biopsy finding was not reported, but all case patients had nephrotic syndrome on presentation.[@bib7], [@bib16], [@bib21], [@bib26] In these case reports, there were poor outcomes associated with steroid use, including death in 7 patients from diverse causes. Corticosteroid treatment in such cases can predispose to the development of hyperinfection syndrome (systemic dissemination of infection) and worsening sepsis, possibly by steroid-induced suppression of eosinophil and lymphocyte activation.[@bib28]

In 4 previously reported cases, nephrotic syndrome improved after treatment of StrS infection with antihelmintic drugs alone, suggesting a direct causal relationship between this infectious agent and the glomerular injury,[@bib7], [@bib18], [@bib22], [@bib25] similar to the treatment response observed in our case. Because cases of podocytopathy associated with infection lack glomerular immune-type deposits, it is likely that the pathogenesis relates to immunologic activation and production of 1 or more circulating "permeability factors" that induce podocyte injury. Given his predisposition to podocytopathy before documented Strs infection, the recent development of parasitic infection was likely the precipitating immune stimulus, possibly via production of a circulating cytokine or other factor with podocyte dysregulatory potential. We opted to treat the StrS infection while avoiding steroid therapy to minimize the risk of aggravating StrS infection. All previous reported cases reviewed here ([Table 1](#tbl1){ref-type="table"}) demonstrate the importance of detecting underlying StrS infection in patients with nephrotic syndrome, because steroid therapy can promote hyperinfection, disseminated strongyloidiasis, and death.

Interestingly, an unrelated antihelmintic agent, levamisole, has been used as a nontoxic alternative to steroids in patients with minimal change disease who lack helmintic infection.[@bib29], [@bib30] Although its mechanism of action is unknown, the ability of this agent to induce remission of primary nephrotic syndrome suggests the potential for direct podocyte effects. Thus we cannot exclude the possibility that ivermectin also exerts direct effects on the podocyte that are independent of its antimicrobial effect.

Parasitic glomerulopathies have also been identified in patients infected with malaria, schistosomiasis, filariasis, kala-azar, trypanosomiasis, toxoplasmosis, and echinococcosis.[@bib28] The clinical manifestations vary in these different infectious settings, ranging from mild abnormalities on urinalysis, to subnephrotic proteinuria or nephrotic syndrome, to acute kidney injury. Nephrotic syndrome as a result of parasitic glomerulopathy has been reported only in malaria, schistosomiasis, filariasis, and cysticercosis.[@bib28] Most of the associated glomerulopathies are immune complex mediated, including membranous and membranoproliferative patterns of injury. Recovery after successful treatment of these parasites has been reported in patients with falciparum malarial nephropathy, schistosomal glomerulopathies, and cysticercosis-related nephrotic syndrome.[@bib28]

In conclusion, we believe that StrS infection in our patient acted as an immunologic trigger for relapse of nephrotic syndrome due to tip variant FSGS. Supportive evidence includes the close temporal association of explosive nephrotic syndrome with active Strs infection and the complete resolution of nephrotic syndrome following antihelmintic treatment alone. The nature of the circulating "permeability factor" that mediates podocytopathy secondary to Strs is unknown. Steroid therapy is usually first-line therapy for primary podocytopathies.[@bib31] Our case illustrates the importance of identifying potential infectious pathogens that can be specifically targeted with antimicrobial therapy while avoiding the risks of immunosuppression.

Disclosure {#sec4}
==========

All the authors declared no competing interests.

The authors acknowledge Dr Robert Yohannan (Huntington, NY) for the initial information and care regarding this patient.

[^1]: F, female; FSGS, focal segmental glomerulosclerosis; M, male; MCD, minimal change disease; MPGN, membranoproliferative glomerulonephritis; NB, no biopsy.
